Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.43 |
| ▸ | TDO2 | P48775 | 10/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383727 | 0.85 | CYP19A1 (0.50) | IDO1TDO2GRM5CYP19A1KCNA5 | |
| SCHEMBL4381298 | 0.78 | CLK4 (0.42) | IDO1TDO2CLK4GRM5KCNA5 | |
| SCHEMBL4380408 | 0.76 | CYP19A1 (0.42) | LRRK2CLK4TNFGRM5CDC7 | |
| SCHEMBL10360256 | 0.74 | TSHR (0.46) | IDO1TDO2TNFKCNA5 | |
| SCHEMBL4413455 | 0.71 | IDO1 (0.42) | IDO1TDO2IDO2CDC7KCNA5 | |
| SCHEMBL2939744 | 0.69 | GRM4 (0.44) | IDO1CLK4TNF | |
| SCHEMBL13589661 | 0.69 | S1PR1 (0.41) | TNF | |
| SCHEMBL4083138 | 0.68 | ENPP2 (0.47) | IDO1CLK4TNFCYP19A1 | |
| SCHEMBL4386224 | 0.68 | IDO1 (0.57) | IDO1 | |
| Pyridine SCHEMBL28318117 | 0.67 | CLK4 (0.52) | IDO1CLK4GRM5CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | IDO1 305/4885TDO2 210/4885LRRK2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.